Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review

Sawayama, Hiroshi; Miyamoto, Yuji; Ogawa, Katsuhiro; Ohuchi, Mayuko; Hisano, Yuki; Kato, Moeko; Tubakihara, Hiroki; Yoshida, Naoya; Baba, Hideo

doi:10.1186/s40792-022-01580-w

Surgical Case Reports

Table 1 Summary of case reports of pathologic complete response after treatment with immune checkpoint inhibitors for colorectal cancer

From: Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review

Case	Age	Sex	Location	BRAF	RAS	Patho	Diameter	Drug	Cycle	Line	Pathological examination	Survival	Characteristic	References
Biopsy cases
1	54	M	C	Mut	Wt	N.A	41	10 mg/kg pembro	16	3	Distant LN	> 2y	BRAF mutant CRC	Discov Med. 2016 21(117):341–7
2	81	M	R	–	–	Por	53	Pembro	11	NAC	Rectum	17 m		J Natl Compr Canc Netw. 2020 18(7):798–804. [8]
3	55	M	A	–	–	N.A	30	IPI Nivo	3	NAC	Rectum	12 m	TMB 21.3 mut./megabase	J Natl Compr Canc Netw. 2020 18(7):798–805. [8]
4	62	W	R			N.A	N.A	Nivo	6	2	Rectum	1y	Lynch syndrome	Oncoimmunology. 2019 19;8(12):e1663109. [13]
Resection cases
1	38	F	R	–	–	Tub2/Muc	N.A	FOLFOX + pembro	7	NAC	Rectum	10 m	Lynch syndrome Combination therapy	J Natl Compr Canc Netw. 2020 18(7):798–806. [8]
2	50	M	A	Wt	Wt	Tub2	90	Nivo	18 m	2	Peritoneal recurrence	9 m	Cytoreductive surg for peritoneal recurrence	BMC Gastroenterol. 2022 10;22(1):17 [9]
3	28	F	R	Wt	Mut	N.A	N.A	Nivo	12	2	Rectum	N.A	Dense lymphoplasmacytic infiltrate	J Cancer Res Ther 2021;17(6):1552–1555. [10]
4	33	M	R	–	–	Tub2	N.A	IPI Nivo	1	NAC	Rectum	N.A	Lynch syndrome, Stage III MSH2 (-) and MSH6 (-)	Oncologist.2021;26(12):e2110-e2114. [11]
5	27	F	R	–	–	Tub1	N.A	IPI Nivo	3	1	Rectum	6 m	RT Lynch syndrome,	Eur J Cancer. 2020;135:75–77. [12]
6	27	M	R	Wt	Wt	Muc	80	Nivo	6	NAC	Rectum	> 1y	TMB high, ATR, PMRM1, ARID2, SMARCA4 mut	Oncoimmunology. 2019 19;8(12):e1663108. [13]
7	45	M	S	–	–	Tub2	73	FOLFOX + pembro	6	3	Sigmoid colon	N.A		Oncology. 2022 8;36(2):115–119. [14]
8	45	M	A	–	–	Por	110	Pembro	20	2	Peritoneal meta	14 m	Peritoneal metastasis	Clin J Gastroenterol. 2022;15(1):134–139. [15]
9	41	F	S	Wt	Mut	N.A	113	Pembro	12	3	Liver	N.A	Lynch syndrome,	Chemotherapy. 2018 Apr 5;63(2):90–94. [16]
10	28	F	S	Wt	Mut	Por	N.A	FOLFOX + pembro	2 m	1	Colon, liver, LN	N.A	FoundationOne	Clin Colorectal Cancer. 2018 Jun;17(2):e229-e232. [17]

mut mutant, wt wild type, N.A. not available, pembro pembrolizumab, LN lymph node, NAC neoadjuvant chemotherapy

Back to article page